ID

40515

Beschrijving

Study ID: 101468/218 Clinical Study ID: SKF-101468/218 Study Title:A Single-Blind, Randomised, Placebo-Controlled, Parallel-Group, Multicentre, Phase IIa Study to Determine the Pharmacokinetics and Tolerability of Ropinirole in Patients Suffering from Restless Legs Syndrome (RLS) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Sponsor: GlaxoSmithKline Phase: phase 2 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: requip Study Indication: Restless Legs Syndrome

Trefwoorden

Versies (2)
  1. 29-04-20 29-04-20 -
  2. 08-05-20 08-05-20 -
Houder van rechten

GlaxoSmithKline

Geüploaded op

29 april 2020

DOI

Voor een aanvraag inloggen.

Licentie

Creative Commons BY-NC 4.0
Model Commentaren :

Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.

Terug naar het model Commentaren
Itemgroep Commentaren voor :

Item Commentaren voor :

U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.

Pharmacokinetics and Tolerability of Ropinirole in Patients Suffering from Restless Legs Syndrome 101468/218

Engels

Dose Level 1, Day1 - Vital Signs Post Dose; Adverse Event

1 Formulieren  
Administrative
Beschrijving

Administrative

Alias
UMLS CUI-1
C1320722
Patient Number
Beschrijving

Patient Number

Datatype

text

Alias
UMLS CUI [1]
C2348585
Centre Number
Beschrijving

Centre Number

Datatype

text

Alias
UMLS CUI [1,1]
C0600091
UMLS CUI [1,2]
C0019994
Adverse Event
Beschrijving

Adverse Event

Alias
UMLS CUI-1
C0877248
+2 hrs - Any Adverse Events?
Beschrijving

If "Yes" record all details on an Adverse Event page at back of CRF.

Datatype

boolean

Alias
UMLS CUI [1]
C0877248
Next Day (+12hrs) by telephone - Any Adverse Events?
Beschrijving

If "Yes" record all details on an Adverse Event page at back of CRF.

Datatype

boolean

Alias
UMLS CUI [1]
C0877248
In the Investigator’s opinion, is it safe for the patient to continue dosing at home?
Beschrijving

Y - Ensure patient returns home with their study medication and diary card N - Select a dosing strategy from options below and tick the relevant box

Datatype

boolean

Alias
UMLS CUI [1,1]
C0805733
UMLS CUI [1,2]
C2603343
UMLS CUI [1,3]
C4534363
If it is not safe for the patient to continue dosing at home, select a dosing strategy from options below and tick the relevant
Beschrijving

If it is not safe for the patient to continue dosing at home, select a dosing strategy from options below and tick the relevant

Datatype

integer

Alias
UMLS CUI [1,1]
C0805733
UMLS CUI [1,2]
C2603343
UMLS CUI [1,3]
C4534363
UMLS CUI [2,1]
C0178602
UMLS CUI [2,2]
C0679199
Terug naar het begin van de pagina

Similar models

Dose Level 1, Day1 - Vital Signs Post Dose; Adverse Event

1 Formulieren
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
Item Group
Administrative
C1320722 (UMLS CUI-1)
Patient Number
Item
Patient Number
text
C2348585 (UMLS CUI [1])
Centre Number
Item
Centre Number
text
C0600091 (UMLS CUI [1,1])
C0019994 (UMLS CUI [1,2])
Item Group
Adverse Event
C0877248 (UMLS CUI-1)
+2 hrs - Any Adverse Events?
Item
+2 hrs - Any Adverse Events?
boolean
C0877248 (UMLS CUI [1])
Next Day (+12hrs) by telephone - Any Adverse Events?
Item
Next Day (+12hrs) by telephone - Any Adverse Events?
boolean
C0877248 (UMLS CUI [1])
In the Investigator’s opinion, is it safe for the patient to continue dosing at home?
Item
In the Investigator’s opinion, is it safe for the patient to continue dosing at home?
boolean
C0805733 (UMLS CUI [1,1])
C2603343 (UMLS CUI [1,2])
C4534363 (UMLS CUI [1,3])
Item
If it is not safe for the patient to continue dosing at home, select a dosing strategy from options below and tick the relevant
integer
C0805733 (UMLS CUI [1,1])
C2603343 (UMLS CUI [1,2])
C4534363 (UMLS CUI [1,3])
C0178602 (UMLS CUI [2,1])
C0679199 (UMLS CUI [2,2])
If it is not safe for the patient to continue dosing at home, select a dosing strategy from options below and tick the relevant
Code List
If it is not safe for the patient to continue dosing at home, select a dosing strategy from options below and tick the relevant
CL Item
TRY AGAIN: Patient will receive the next days dose in the clinic. Complete an Extra Clinic Visit section of the CRF for this visit. (1)
CL Item
MTD DETERMINED: No further attempts at this dose level will be made. Complete Last Clinic Visit section in the CRF. (2)
Terug naar het begin van de pagina 

Contact

Gebruik dit formulier voor feedback, vragen en verbeteringsvoorstellen.

Velden gemarkeerd met een * zijn verplicht.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial